Microorganisms (Basel), 2021-07, Vol.9 (8), p.1605
2021
Details
- Autor(en) / Beteiligte
- Titel
- Gut Dysbiosis during COVID-19 and Potential Effect of Probiotics
- Ist Teil von
- Microorganisms (Basel), 2021-07, Vol.9 (8), p.1605
- Ort / Verlag
- Switzerland: MDPI AG
- Erscheinungsjahr
- 2021
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus of the family , causes coronavirus disease 2019 (COVID-19), an influenza-like disease that chiefly infects the lungs through respiratory transmission. The spike protein of SARS-CoV-2, a transmembrane protein in its outer portion, targets angiotensin-converting enzyme 2 (ACE2) as the binding receptor for the cell entry. As ACE2 is highly expressed in the gut and pulmonary tissues, SARS-CoV-2 infections frequently result in gastrointestinal inflammation, with presentations ordinarily ranging from intestinal cramps to complications with intestinal perforations. However, the evidence detailing successful therapy for gastrointestinal involvement in COVID-19 patients is currently limited. A significant change in fecal microbiomes, namely dysbiosis, was characterized by the enrichment of opportunistic pathogens and the depletion of beneficial commensals and their crucial association to COVID-19 severity has been evidenced. Oral probiotics had been evidenced to improve gut health in achieving homeostasis by exhibiting their antiviral effects via the gut-lung axis. Although numerous commercial probiotics have been effective against coronavirus, their efficacies in treating COVID-19 patients remain debated. In ClinicalTrials.gov, 19 clinical trials regarding the dietary supplement of probiotics, in terms of and mixtures of and , for treating COVID-19 cases are ongoing. Accordingly, the preventive or therapeutic role of probiotics for COVID-19 patients can be elucidated in the near future.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2076-2607eISSN: 2076-2607DOI: 10.3390/microorganisms9081605Titel-ID: cdi_doaj_primary_oai_doaj_org_article_7fe29909ccf04778bf299ded0c07f305
- Format
- –
- Schlagworte
- ACE2, Amino acids, Angiotensin, Angiotensin-converting enzyme 2, Bacteria, Bifidobacteria, Campylobacter, Clinical trials, Commensals, Complications, Coronaviruses, COVID-19, Cramps, Cytokines, Depletion, Diet, Dietary supplements, Digestive system, Digestive tract, Disease transmission, Dysbacteriosis, Feces, Glycoproteins, gut microbiome, Homeostasis, Infections, Inflammation, Inflammatory bowel disease, Influenza, Intensive care, Intestine, Lactobacillus, Lungs, Microbiomes, Microbiota, Microorganisms, Opportunist infection, Pathogens, Patients, Peptidyl-dipeptidase A, Perforation, Pneumonia, Probiotics, Proteins, Respiratory diseases, Review, RNA viruses, SARS-CoV-2, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus 2, Spike protein, Tumor necrosis factor-TNF, Viral diseases, Viral infections, Viruses